Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684485 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT04684485: Completed Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT04684485 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 250 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04684485, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
Primary Outcome
Based on gross morphological findings, scores will be assigned on a 4-point scale \['0' (absent), '1' (mild), '2' (moderate) and '3' (severe)\] for each clinical sign. The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.
Interventions
- DRUG Placebo
- DRUG SCD-044_Dose 1
- DRUG SCD-044_Dose 2
- DRUG SCD-044_Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2025-03-18 |
| Phase | Phase 2 |
What the finished NCT04684485 record still lists
NCT04684485 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04684485 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04684485 about?
NCT04684485 is a clinical study titled "To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis". This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
What is the current status of trial NCT04684485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2021-07-30. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT04684485?
The interventions under investigation include: Placebo (DRUG), SCD-044_Dose 1 (DRUG), SCD-044_Dose 2 (DRUG), SCD-044_Dose 3 (DRUG).
Who is sponsoring clinical trial NCT04684485?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04684485's enrollment target sits among peer trials
250 222nd of 2000 higher than 1,768 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI